Related references
Note: Only part of the references are listed.Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing
Joerg Felsberg et al.
ACTA NEUROPATHOLOGICA (2010)
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
J. Dunn et al.
BRITISH JOURNAL OF CANCER (2009)
High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations
Emilia Jesien-Lewandowicz et al.
CANCER GENETICS AND CYTOGENETICS (2009)
Association Between MGMT Promoter Hypermethylation and p53 Mutation in Glioblastoma
Jamal Shamsara et al.
CANCER INVESTIGATION (2009)
Genetic alterations and signaling pathways in the evolution of gliomas
Hiroko Ohgaki et al.
CANCER SCIENCE (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pediatric glioblastomas: A histopathological and molecular genetic study
Vaishali Suri et al.
NEURO-ONCOLOGY (2009)
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
Michael A. Vogelbaum et al.
NEURO-ONCOLOGY (2009)
Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study
L. Huang et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2009)
Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma -: Relationship between immunohistochemistry and methylation analysis
Ken Sasai et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach
David Capper et al.
ACTA NEUROPATHOLOGICA (2008)
Temozolomide and radiation in low-grade and anaplastic gliomas: Temoradiation
David Schiff
CANCER INVESTIGATION (2007)
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas
Eva M. Grasbon-Frodl et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Long-term survival with glioblastoma multiforme
Dietmar Krex et al.
BRAIN (2007)
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
Judith Wm Jeuken et al.
LABORATORY INVESTIGATION (2007)
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas
Dai Ishii et al.
NEUROLOGIA MEDICO-CHIRURGICA (2007)
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis
Thomas Mikeska et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival
Marica Eoli et al.
CLINICAL CANCER RESEARCH (2007)
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide
Olivier L. Chinot et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma
Andrew M. Donson et al.
PEDIATRIC BLOOD & CANCER (2007)
MGMT methylation:: A marker of response to temozolomide in low-grade gliomas
Sibille Everhard et al.
ANNALS OF NEUROLOGY (2006)
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
Jill A. Maxwell et al.
MOLECULAR CANCER THERAPEUTICS (2006)
O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas:: Results from the CCG-945 cohort
Ian F. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing
Richard J. Shaw et al.
NUCLEIC ACIDS RESEARCH (2006)
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas
M Brell et al.
CLINICAL CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
M Möllemann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-primidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy
T Kamiryo et al.
NEUROSURGERY (2004)
Generating mutations but providing chemosensitivity:: the role of O6-methylguanine DNA methyltransferase in human cancer
M Esteller et al.
ONCOGENE (2004)
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz et al.
CLINICAL CANCER RESEARCH (2004)
Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase, π in glioblastoma and the survival of the patients treated with nimustine hydrochloride:: An immunohistochemical analysis
T Anda et al.
NEUROLOGICAL RESEARCH (2003)
Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene
M Nakamura et al.
CARCINOGENESIS (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
